At the start of the year, it looked like the pharma M&A market would get an adrenaline injection – but now, it's more like it’s taken a sleeping pill.» Read More
May 13- Valeant Pharmaceuticals International Inc said on Tuesday it will "improve" its unsolicited $47 billion takeover offer for drugmaker Allergan Inc, a day after the U.S. company rejected the bid.
Pfizer's CEO Ian Read is getting grilled at a hearing in the U.K. over the company's proposed takeover of AstraZeneca, reports CNBC's Meg Tirrell.
The CEO of AstraZeneca told CNBC the U.K. pharmaceutical giant was big enough to thrive alone, but would still consider a takeover bid.
Pfizer hints it could raise its offer for AstraZeneca. The "Squawk on the Street" news team discuss comprehensive tax reform and the drug maker's takeover bid amid British lawmakers growing concern about job losses.
*AT&T in talks to buy DirecTV, sources say. NEW YORK, May 13- U.S. stock index futures pointed to a flat open on Tuesday as investors found few reasons to keep pushing shares higher with major indexes coming off record closes and economic data painting a mixed picture of the economy.
Slow and steady wins the race. That lesson from the Aesop fable about "The Tortoise and the Hare" can also apply to the stock market, according to stock picker Oscar Schafer.
U.S. stock index futures indicated a higher start to Wall Street trade on Tuesday, with shares in Asia and Europe boosted.
LONDON, May 13- Intervening in Pfizer's proposed acquisition of AstraZeneca using public interest rules is "quite tricky" and could be a lengthy process, British business minister Vince Cable said on Tuesday.
CNBC's Meg Tirrell reports the latest details on U.S. drug maker Pfizer's bid to buy AstraZeneca.
*Pfizer hints at improved offer if AstraZeneca engages. LONDON, May 13- U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by UK lawmakers on his commitment to British research spending and jobs.
Some of the names on the move ahead of the open.
LONDON, May 13- AstraZeneca Chief Executive Pascal Soriot said his company's board would be obliged to consider a compelling offer from Pfizer, despite rebuffing the U.S. drugmaker's approaches so far. "It's impossible to say we would never accept any offer," he told a committee of British lawmakers on Tuesday.
*AT&T in talks to buy DirecTV: sources. *Gains this year have come on improving signs of domestic growth, though traders continue to worry about the pace of economic expansion as well as tensions between Ukraine and Russia, which many fear could escalate into further violence.
CNBC's Meg Tirrell reports the latest details on U.S. drugmaker Pfizer's bid to buy AstrZeneca.
LONDON, May 13- AstraZeneca Chief Executive Pascal Soriot said Pfizer's plan to cut its tax bill by re-domiciling to Britain if it buys the smaller British drugmaker posed a reputational risk. The U.S. drugmaker has stirred up a political storm with its $106 billion plan to acquire AstraZeneca, which has been rebuffed by the smaller British company.
U.S. drugmaker Pfizer's boss was grilled by UK lawmakers on his commitment to British research spending and jobs.
LONDON, May 13- British drugs company AstraZeneca said its bigger U.S. rival Pfizer was making an "opportunistic attempt" to buy the company for a price that didn't reflect the value of its "exciting pipeline" of new drugs.
*Pfizer hints at improved offer if AstraZeneca engages. LONDON, May 13- U.S. drugmaker Pfizer suggested it could raise its proposed $106 billion offer if AstraZeneca engaged in talks, as its boss was grilled by UK lawmakers on his commitment to British research spending and jobs.
Barbara Ryan, FTI Consulting, weighs in on Pfizer's bid to acquire AstraZeneca, and what's driving consolidation in the pharma space.
Pfizer CEO Ian speaks before British lawmakers on his company's bid for AstraZeneca, reports CNBC's Meg Tirrell.